Share:
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ( Navidea or the Company ), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the granting of a National Institutes of Health ( NIH ) award to the University of California San Diego School of Medicine for the proposal entitled, Renal Molecular Imaging of Mesangial Cell Function with Tc-99m-Tilmanocept. The award (Project Number: 1R01DK127201-01), from the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH, was granted to Co-Principal Investigators UC San Diego faculty Carl Hoh, MD and David Vera, PhD, of the Department of Radiology, and Charles Ginsberg, MD, MAS, of the Department of Medicine, Division of Nephrology.
Navidea Biopharmaceuticals Announces Acceptance of Therapeutics Focused Abstract for Presentation at the Frontiers in Cancer Immunotherapy Symposium streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.